Floatz logo

Tigecycline

Obesity

Manjunath Prakash PaiSmall moleculePhase 4 / ApprovedDormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
59/ 100

Competitive context

575 Active assets in the Obesity cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Tirzepatide
LABORATORIOS INDUFAR
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB

View all 50 →

Same molecule, other indications

Tigecycline is also rated in:

pulmonary non-tuberculous mycobacterial infectionDormant
CCC
Indicative ·
53 / 100
View asset →
mycobacterial infectious diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
cirrhosis of liverDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →